



Available online at www.sciencedirect.com





Journal of Sport and Health Science 00 (2023) 1-12

Review

Physical activity and amyloid beta in middle-aged and older adults: A systematic review and meta-analysis

María Rodriguez-Ayllon^{a,†}, Patricio Solis-Urra^{b,c,d,†}, Cristina Arroyo-Ávila^b, Miriam Álvarez-Ortega^b, Pablo Molina-García^e, Cristina Molina-Hidalgo^f, Manuel Gómez-Río^d, Belinda Brown^{g,h}, Kirk I. Erickson^{b,f,g,h,i}, Irene Esteban-Cornejo^{b,j,*}

^a Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, GD 3015, the Netherlands

^b Department of Physical Education and Sports, Faculty of Sport Sciences, Sport and Health University Research Institute (iMUDS),

University of Granada, Granada 18071, Spain

^c Faculty of Education and Social Sciences, Universidad Andres Bello, Viña del Mar 2531015, Chile

^d Department of Nuclear Medicine, Virgen de las Nieves University Hospital, Institute of Biosanitary Research of Granada (IBS), Granada 18014, Spain

^e Physical Medicine and Rehabilitation Service, Virgen de las Nieves University Hospital, Institute of Biosanitary Research of Granada (IBS), Granada 18014, Spain ^f Department of Psychology, University of Pittsburgh, Pittsburgh, PA 15260, USA

^g Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA 6150, Australia

^h School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA 6027, Australia

Advent Health Research Institute, Neuroscience Institute Orlando, Orlando, FL 32803, USA

^j Physiopathology of Obesity and Nutrition Research Center (CIBERobn), Institute of Health Carlos III (ISCIII), Madrid 28029, Spain

Received 11 October 2022; revised 11 February 2023; accepted 30 June 2023

2095-2546/© 2023 Published by Elsevier B.V. on behalf of Shanghai University of Sport. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)

Abstract

Background: One of the pathological hallmarks distinguishing Alzheimer's disease from other dementias is the accumulation of amyloid beta (A β). Higher physical activity is associated with decreased dementia risk, and one potential path could be through A β levels modulation. We aimed to explore the relationship between physical activity and A β in middle-aged and older adults.

Methods: A systematic search of PubMed, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trials, and SPORTDiscus was performed from inception to the 28th of April 2022. Studies were eligible if they included physical activity and A β data in adults aged 45 years or older. Multi-level meta-analyses of intervention and observational studies were performed to examine the role of physical activity in modulating A β levels.

Results: In total, 37 articles were included (8 randomized controlled trials, 3 non-randomized controlled trials, 4 prospective longitudinal studies, and 22 cross-sectional studies). The overall effect size of physical activity interventions on changes in blood A β was medium (pooled standard-ized mean difference = -0.69, 95% confidence interval (95%CI): -1.41 to 0.03; $I^2 = 74.6\%$). However, these results were not statistically significant, and there were not enough studies to explore the effects of physical activity on cerebrospinal fluid (CSF) and brain A β . Data from observational studies were examined based on measurements of A β in the brain using positron emission tomography scans, CSF, and blood. Higher physical activity was positively associated with A β only in the CSF (Estimate r = 0.12; 95%CI: 0.05–0.18; $I^2 = 38\%$).

Conclusion: Physical activity might moderately reduce blood $A\beta$ in middle-aged and older adults. However, results were only near statistical significance and might be interpreted with caution given the methodological limitations observed in some of the included studies. In observational studies, higher levels of physical activity were positively associated with $A\beta$ only in CSF. Therefore, further research is needed to understand the modulating role of physical activity in the brain, CSF, and blood $A\beta$, as well as its implication for cognitive health.

Keywords: Aging; Cognitive impairment; Dementia; Exercise; PET

1. Introduction

Peer review under responsibility of Shanghai University of Sport. * Corresponding author.

[†] These two authors contributed equally to this work.

Life expectancy is increasing globally in tandem with the number of people living with dementia and cognitive impairment. In particular, Alzheimer's disease (AD) is the major cause of cognitive decline and dementia worldwide.¹ AD is characterized by severe progressive memory impairments related to deposition

E-mail address: ireneesteban@ugr.es (I. Esteban-Cornejo).

of amyloid beta (A β) plaques in brain extracellular spaces causing cortical dysfunction and neuronal loss.² A β accumulation can be detected in a preclinical stage of AD, before clinical symptoms emerge,³ and can be measured in the brain and the cerebrospinal fluid (CSF) via positron emission tomography (PET) and lumbar puncture, respectively.⁴ Several studies indicated an inverse correlation between global cortical amyloid PET and CSF A β levels.^{5–7} One of the hypotheses is that A β levels gradually decrease in the CSF in AD because of the preferential sequestration as insoluble deposits in brain.⁵ Recently, an increasing number of studies have also explored blood A β as a blood biomarker for AD. However, the published results regarding the correlation of blood A β with brain and CSF A β are conflicting, and many factors have been reported to impact blood A β levels and their association with AD biomarkers.⁸

Potentially modifiable factors (e.g., lifestyle factors) have garnered increased attention as possible approaches for reducing AB accumulation in the brain and, in turn, delaying the progression of AD.⁹ Animal models indicate that physical activity may delay, prevent, or treat AD by impacting AB plaque deposition.^{10–12} In humans, researchers have used several measurements of $A\beta$ in the brain, CSF, and blood to explore the effects of physical activity on AB levels. However, the results obtained were inconsistent.¹³⁻¹⁷ For instance, some intervention studies have found that the level of $A\beta$ in the brain does not change after a physical activity intervention.^{13,14} Similar results were found by Jensen et al.,¹⁵ who concluded that physical activity did not affect CSF AB after a 16-week intervention. In contrast, other studies established that physical activity reduces the levels of blood circulating AB.^{16,17} There are several possible explanations for these inconsistencies, including the study design, population characteristics, or $A\beta$ measurement. Therefore, a systematic synthesis of the current evidence that considers potential moderators is needed to confirm or refute the hypothesis that physical activity modulates AB levels. Clarity on this issue would improve our understanding of whether A β modulation is one of the mechanisms through which physical activity might decrease dementia risk. This knowledge would no doubt contribute to the development of more effective physical activity interventions for reducing cognitive decline in older adults.

Two previous narrative reviews have explored the relationship between physical activity and AB.^{18,19} Specifically, Ebrahimi et al.¹⁸ suggested that physical activity could improve cognitive function by reducing AB levels. In contrast, Brown et al.¹⁹ concluded that although evidence in animals seems consistent, evidence of the influence of physical activity on AB in humans is still scarce. While these reviews contributed important insights to the field, the absence of objective and systematic study selection criteria arguably leads to a number of methodological biases (e.g., the author's interpretation and conclusions). In 2015, de Souto Barreto et al.²⁰ performed a systematic review to explore the association of physical activity and AD biomarkers, including AB, in humans. However, evidence at that time was limited. Only 5 cross-sectional studies were included, and their results were contradictory (i.e., 3 positive and 2 null associations). In 2019, Frederiksen et al.²¹ carried out a systematic review of observational studies to explore the association of physical activity with AD biomarkers. In brief, they concluded the majority of the identified studies did not find a significant association between physical activity and $A\beta$.²¹ This, together with the lack of quantitative synthesis of data (e.g., a meta-analysis), and the fact that literature in the field has grown substantially over the past few years, has limited the ability of prior work to draw solid conclusions about the effect of physical activity on $A\beta$ in humans. Consequently, an updated systematic review is needed to understand the role of physical activity on $A\beta$ levels—and it must include both intervention studies, to provide causal evidence, and observational studies, to provide complementary information in an emerging field that is still in its infancy.

Therefore, the aim of the current systematic review was to determine the overall effect of physical activity on A β by conducting a systematic review and meta-analysis of available intervention studies (including randomized controlled trials (RCTs) and non-RCTs). Due to the expected lack of intervention studies, we also aimed to synthesize the observational evidence by conducting a meta-analysis of observational studies (including cross-sectional and prospective longitudinal studies) testing the association between physical activity and A β in middle-aged and older adults.

2. Methods

This study was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.²² Additionally, the systematic review protocol was registered in the international Prospective Register of Systematic Reviews (PROSPERO) (CRD42020184203).

2.1. Search strategy

The literature search was carried out from inception to 28th April 2022 in PubMed, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trials, and SPORTDiscus. The search strategy used for all databases is described in Table 1. We extracted all studies from the different databases into an EndNote Library (Version X7, Clarivate, Philadelphia, PA, USA). Relevant articles were screened by titles and abstract by 2 independent researchers (CAA and MÁO). Full-text articles considered acceptable for review were examined to determine final eligibility by the same 2 researchers (CAA and MÁO). In case of disagreement, consensus was achieved through discussion and, when required, the opinion of a third researcher (MRA) was considered.

2.2. Eligibility criteria

Overall, the inclusion criteria were: (a) age criterion: adults aged 45 years and older; (b) language criterion: no restrictions; (c) exposure: physical activity; for experimental studies, physical exercise interventions (a form of physical activity that is planned, structured, repetitive, and performed to improve health or fitness) not combined with another type of intervention (e.g., cognitive/ diet interventions) were included; for observational studies,

Physical activity and amyloid beta

Table 1
Search strategy.

Databases	Search strategy	Limits
PubMed, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trials, SPORTDiscus	 ("A-beta" OR "amyloid" OR "Aβ" OR "beta-Peptide" OR "beta-Protein*" OR "β-protein" OR "Amyloidosis") AND ("Exercise" OR "Sports" OR "physical exercise" OR "Aerobic exercise" OR athletic OR "Motor Activity" OR "Physical activity" OR "Locomotor activity" OR "Training" OR "Moderate physical activity" OR "Vigorous physical activity" OR "Moderate-to-vigorous physical activity" OR "NVPA" OR "Sedentary" OR "Inactivity" OR "Aerobic activities" OR "Aerobic activity" OR "Cardiovascular activities" OR "Aerobic activity" OR "Cardiovascular activities" OR "Aerobic activity" OR "Cardiovascular activities" OR "Physical conditioning" OR "Resistance training" OR "Strength training" OR "Lifestyle activities" OR "Lifestyle activity" OR "Recreational activities" OR "Gardiovas or "dance" OR "dancing" OR "Balance training" OR "Functional training" OR "stretching" OR "Walk" OR "Walking") AND (adult OR adults OR adulthood OR elderly OR "Oldest Old") PubMed (Filters activated: Humans, Middle Aged + Aged: 45+ years) 	Publication date from incep- tion to 2022/04/28.

3

objective or self-reported physical activity measurements were included; (d) control group criterion, understood as "treatment as usual" or "stretching": intervention studies should have either an inactive, active, or no control group (we considered a control group as active when participants from the control group practiced any type of exercise but stretching; only the primary subset of studies (i.e., physical exercise group *vs*. control group) were included in the meta-analyses); (e) outcome: A β in the brain using PET, CSF, or blood; A β ratios (A β 42/40 or A β 40/42) were also included in this review; (f) study design: we included cross-sectional studies, longitudinal cohort studies and intervention studies (RCTs and non-RCTs).

2.3. Data extraction

Two researchers (CAÁ and PSU) extracted data from the selected studies to a customized data extraction form developed and piloted a priori by the review team. We extracted the following items: study background (name of the first author, year, and country), total risk of bias score, sample characteristics (target population, number of participants, participants' age, and sex), design, measures and instruments used to assess both AB and physical activity. For intervention studies, we also extracted intervention details (exercise type, frequency in number of sessions per week, session duration, intervention duration in weeks, exercise intensity) together with control conditions. Information extracted in the tables was doublechecked by 3 experienced researchers (IEC, PMG, and MRA). Possible disagreements were discussed by the researchers until a consensus was reached. Lastly, in cases of incomplete/ missing data, we contacted the corresponding authors for data requests.

2.4. Risk of bias

The risk of bias was evaluated independently by 2 researchers (CAA and MAO) and disagreements were resolved in a consensus meeting with IEC, PMG, MRA, and CMH. The risk of bias was evaluated using the Joanna Briggs Institute Critical Appraisal Tool for Systematic Reviews,²³ which has been used in previous reviews.^{24–26} The studies were categorized

with an overall risk of bias score as used in previous studies.²⁴ Specifically, the studies were considered as "low risk" when 75% of items were scored as "yes" (criterion met).

2.5. Synthesis of the evidence

Multi-level meta-analyses of intervention and observational studies were performed using *R* Statistical Software (Version 4.2.2; https://www.r-project.org/contributors.html) and the *metafor* package Version 3.8.1 (Wolfgang Viechtbauer, Maastricht University, Netherlands). A separate synthesis of the evidence was performed for studies that assess $A\beta$ in the CSF, brain and blood. Statistical significance was set at a *p* value of less than 0.05.

2.5.1. Multi-level meta-analysis for intervention studies

Standardized mean differences (SMD) between the exercise and control groups were computed. Weighted mean differences were calculated using a random effects model. Heterogeneity was measured using the l^2 statistic (the percentage of total variability attributed to between-study heterogeneity). SMD was calculated using Hedges' adjusted g (similar to Cohen's d). ESs of 0.2, 0.4, and 0.8 were considered small, medium, and large, respectively. The publication bias was assessed by a funnel plot and the Egger's regression asymmetry test, considering the level of significance of <0.1.²⁷ To run the Egger's test, the random-effects model was modified to include the standard error of the effect size as a moderator.

Posteriori exploratory moderation analyses were performed using sex and type of intervention (aerobic interventions *vs.* others) as categorical variables and mean of age and total intervention duration (weeks \times sessions \times minutes/session) as continuous moderators (meta-regression). In addition, exploratory subgroup comparisons were calculated for categorical variables (i.e., sex and type of intervention).

2.5.2. Meta-analysis for observational studies

For studies reporting associations between physical activity and $A\beta$, correlation coefficients were extracted along with

sample size. Wherever correlation values were not provided but studies met the inclusion criteria, correlation coefficients were calculated using the available data according to the analysis presented using *esc* package 0.5.1 (Daniel Lüdecke, University Medical Center Hamburg, Germany). Heterogeneity was assessed using the Q statistic (with p < 0.10suggesting statistically significant heterogeneity). A *posteriori* moderator analysis was performed. Specifically, a mixedeffects model was fitted to examine the moderators described below as potential sources of variance. Separate models were fitted to determine the main effects for population characteristics (cognitively normal *vs.* cognitively impaired). The analysis of main effects was interpreted using the 95% confidence interval (95%CI) for the point estimates of each level of a moderator and the statistical significance of the omnibus test.

Funnel plots of the effect size against the standard error of the effect size were visually inspected for small-sample bias, and Egger's test values with 95%CI for funnel plot asymmetry were calculated.^{28–30} To run the Egger's test, the random-effects model was modified to include the standard error of the effect size as a moderator. Small-sample bias was considered to be present when the funnel plot appeared asymmetrical and the intercept of the Egger's test was significantly different from zero (p < 0.10).^{28,29}

2.6. Data sharing statement

The data that support the findings of this study are available from the corresponding authors upon reasonable request.

3. Results

3.1. Study selection and characteristics

The database search revealed a total of 2261 articles, of which 450 were duplicates. Finally, a total of 71 articles were identified for full-text screening. After the full-text screening, 8 RCTs, 3 non-RCT intervention, 4 prospective longitudinal studies, and 22 cross-sectional studies met the inclusion criteria and were subsequently included in this systematic review. Further details about the selection process are shown in Fig. 1. The excluded articles and corresponding reasons for exclusion are shown in Supplementary Table 1. Detailed descriptions of the included intervention and observational studies are provided in Supplementary Tables 2 and 3, respectively.

3.2. Study characteristics of the intervention studies

Sample sizes of included intervention studies ranged from 14¹⁷ to 109¹⁴ participants (Supplementary Table 2). Participants ranged from 55 to 85 years of age.³¹ Five studies included only females.^{17,32–35} In another study, 92% of the total sample was female.¹⁶ Six of 11 studies included cognitively impaired participants (from patients with AD to patients with mild cognitive impairments).^{13,15,31,32,34,36} Most interventions (6 of 11 studies) included aerobic exercise, ^{13–15,31,33,36} while 3 studies included a combination of aerobic and resistance exercises, ^{16,17,34} another included resistance exercise using bands,³² and another Taekwondo.³⁵ Interventions ranged from 8³³ to 52 weeks, ^{13,14} and

the majority implemented 60-min exercise sessions between 3 and 5 times per week. Only 3 studies reported data on intervention adherence,^{14–16} which ranged from 69%¹⁵ to 90%.¹⁶ Most studies did not specify the control group criteria.^{17,32–34} In the studies whose criteria were described, participants from the control group continued their usual routines,¹⁵ received educational sessions,¹⁴ or participated in an active control group (e.g., stretching and balance exercises).^{13,16,36,31} Lastly, 3 studies measured A β in the brain by PET,^{13,14,36} 1 study measured A β in CSF by lumbar puncture,¹⁵ and 7 studies measured A β in the blood (i.e., 4 in plasma,^{16,31,33,34} 2 in serum,^{17,35} and 1 study did not specify plasma or serum³²).

3.3. Study characteristics of the observational studies

3.3.1. Longitudinal studies

Sample sizes ranged from 65³⁷ to 515,³⁸ and participants were aged up to 94 years³⁸ (Supplementary Table 3). Two studies included cognitively normal individuals;^{38,39} another 2 included cognitively impaired participants.37,40 Physical activity was assessed by validated self-reported ques-tionnaires^{37–39} or through an interview.⁴⁰ No studies assessed physical activity with objective measures (e.g., accelerometry). Regarding the outcome, one study assessed brain AB levels with carbon 11-labeled Pittsburgh compound B PET,³ one assessed CSF A β with an enzyme-linked immunoassay (ELISA) kit (Fujirebio (formerly Innogenetics), Ghent, Belgium),⁴⁰ and one assessed both brain A β , with carbon 11-labeled Pittsburgh compound B PET, and CSF AB, with an ELISA kit (Innotest; Fujirebio (formerly Innogenetics)).³⁹ Lastly, one of the studies assessed blood $A\beta$ in plasma using a combination of mouse monoclonal antibody 6E10 and two different antibodies specific for AB1-40 and AB1-42, in a double antibody sandwich ELISA.³⁸ Finally, follow-up ranged from $2^{39,40}$ to 3 years.^{38,40}

3.3.2. Cross-sectional studies

Sample sizes ranged from 40⁴¹ to 1108,⁴² and participants were aged up to 97 years⁴³ (Supplementary Table 3). Most of the studies assessed physical activity by self-report questionnaires (80%). The remaining studies utilized interviews,⁴⁴ pedometers,^{45,46} and accelerometry⁴³ to measure physical activity. Regarding the measurements of A β , 9 studies used only PET to measure brain A β ,^{44–52} 4 studies included both PET and CSF measures,^{53–56} and 2 studies used both PET and plasma measurements of A β .^{57,58} Additionally, 3 studies included only CSF samples,^{41,42,59} 2 studies used only plasma samples,^{60,61} and 1 study used postmortem brain samples.⁴³ Only 2 studies used mass-spectrometry assays for assessing A β in CSF⁶² and blood.⁵⁸

3.4. Risk of bias assessment

The percentage of studies that met the criteria for reporting a "low risk of bias" item-by-item is presented in Supplementary Tables 4–7 according to their study design (RCT, non-RCTs, longitudinal cohort studies, and cross-sectional studies, respectively). In addition, the overall risk of bias assessment study-by-study is presented in Supplementary Tables 8–11.

Physical activity and amyloid beta



Fig. 1. Flow diagram for study selection. RCT = randomized controlled trial.

In brief, most of the included studies presented a "high risk" (25% of items were scored as "no" or "unclear"). Specifically, a high risk of bias was detected in 6 of 8 (75%) RCTs, 3 of 3 (100%) non-RCTs, 2 of 4 (50%) longitudinal studies, and 7 of 22 (32%) cross-sectional studies.

3.5. Synthesis of the evidence

3.5.1. Meta-analysis of intervention studies

A meta-analysis of intervention studies conducted on 131 participants is presented in Fig. 2. Compared to the control

M. Rodriguez-Ayllon et al.

Reference - ES	Experimental Mean ± SD n	Control Mean ± SD n	Туре	Dose Weeks/Days/Min	Design	Tissue	lsoform		Weight %	SMD and 95%CI
Baker et al., 2010 ³¹	-21.1 ± 54.93 19	21 ± 56.36 9	Aerobic	24 / 4 / 52	RCT	Blood-P	Αβ42		17.35%	-0.74 (-1.55 to 0.08)
Kim et al., 2018 - ES1 ³³	4.86 ± 4.75 14	0.32 ± 2.39 12	Aerobic (Aquati	c) 16 / 2 / 60	Non-RCT	Blood-S	Αβ42		9.16%	1.14 (0.31 to 1.97)
Kim et al., 2018 - ES2 ³³	2.69 ± 7.41 14	0.32 ± 2.39 12	Aerobic (Land)	16 / 2 / 60	Non-RCT	Blood-S	Αβ42		10.43%	0.40 (-0.38 to 1.18)
Kwon et al., 2007 ¹⁷	-0.07 ± 0.07 7	0.03 ± 0.05 7	Concurrent	12 / 3 / 60	Non-RCT	Blood-S	Αβ	·	13.85%	-1.54 (-2.73 to -0.35)
Baek et al., 2021 ³⁵	-1.06 ± 1.59 10	1.14 ± 5.89 10	Taekwondo	12 / 3 / 60	RCT	Blood-S	Αβ42		16.65%	-0.49 (-1.38 to 0.40)
Hyang-Beum et al., 2021 ³²	-9.37 ± 7.12 11	-0.28 ± 6.13 12	Resistance	8 / 3 / 60	Non-RCT	Blood	Αβ42		16.52%	-1.32 (-2.23 to -0.42)
Zhang et al., 2021 ³⁴	-1.24 ± 0.89 10	-0.02 ± 1.03 10	Concurrent	12/3/60	Non-RCT	Blood-P	Αβ42		16.04%	-1.21 (-2.17 to -0.26)
RE Model: p < 0.001, I ² = 7	4.6%							•	100%	-0.69 (-1.41 to 0.03)
								-3 -2 -1 0 1 2		
							Favo	ors [experimental] Favors [control]		

Fig. 2. Forest plot of pooled effect size and confidence intervals of intervention studies analyzing the effect of physical activity on blood A β . Kim et al.³³ did not report the isoform assessed. 95%CI=95% confidence interval; A β =amyloid beta; Blood-P=blood-plasma; Blood-S=blood-serum; RCT=randomized controlled trials; RE=random effect; SMD=standardized mean difference.

group, exercise interventions had a medium effect on reducing blood AB in middle-aged and older adults (pooled SMD = -0.69, 95%CI: -1.41 to 0.03; $I^2 = 74.6\%$). However, only a few interventions achieved the criteria for being metaanalyzed, and the results were not statistically significant. Two intervention studies were excluded from the meta-analysis due to incomplete data³⁶ and the absence of a control group.¹⁶ Tarumi et al.¹³ was the only study to assess A β locally instead of in the whole brain. In addition, Jensen et al.¹⁵ was the only study to assess AB in the CSF. Lastly, Vidoni et al.¹⁴ was the only study to assess $A\beta$ in the brain. Therefore, we performed our analyses excluding these 5 studies from the pool. Consequently, only studies that assessed $A\beta$ in the blood were included in the meta-analysis. Of note, 1 study³³ assessed A β 30 min after the last session in the 16th week. This complicates the interpretation of the results because it combines into a single measure the acute and chronic effects of the exercise program on A β . Therefore, we ran a sensitivity analysis excluding this study from the general pool and observed the overall effect became significant (pooled SMD = -0.99, 95%CI: -1.41 to -0.58; $I^2 = 0$ %). Due to the limited number of studies included in the meta-analysis, sensitivity analyses (e.g., excluding plasma/serum A β) could not be performed. Lastly, we did not find evidence of publication bias based on visual observation of the funnel plot and Egger's tests (Supplementary Fig. 1).

Moderation analyses showed that participants who attended a combined (i.e., aerobic + resistance training) or non-aerobic (e.g., taekwondo intervention) exercise intervention had larger effects on A β (Omnibus test of moderators = 8.85, p = 0.01; aerobic: SMD = 0.079, 95%CI: -0.844 to 1.002; combined or non-aerobic: SMD = -1.114, 95%CI: -1.853 to -0.375). In addition, subgroup analysis including only females revealed that results remain consistent according to the general effect (SMD = -0.695, 95%CI: -1.570 to 0.181).

Finally, meta-regression analyses (including continuous moderators) showed large effects on older participants (Omnibus test of moderators = 5.291, p = 0.021), and no differences were observed according to the total time of the intervention (Omnibus test of moderators = 0.000, p = 0.984) (Supplementary Fig. 2).

3.5.2. Meta-analysis of observational studies

The meta-analysis of observational studies assessing AB in the brain is shown in Fig. 3. In brief, the overall association of physical activity with brain $A\beta$ was not significant (ES = -0.06, 95%CI: -0.11 to $0.00, I^2 = 49.92\%$). Results did not change when longitudinal studies were excluded from the general pools (ES = -0.06, 95%CI: -0.12 to 0.00, $I^2 = 51.81\%$) (data not shown). The meta-analysis of observational studies that assessed $A\beta$ in the CSF is summarized in Fig. 4. Specifically, the overall effect of physical activity on CSF A β was significant (ES = 0.12, 95%CI: 0.05-0.18, $I^2 = 38\%$). All studies included in this pool had a crosssectional design. Lastly, the overall effect of physical activity on blood A β is presented in Fig. 5. Briefly, the association between physical activity and blood AB was not significant $(ES = -0.06, 95\% CI: -0.15 \text{ to } 0.03, I^2 = 68.02\%)$. When only studies with a cross-sectional design were included, the results remained consistent (pooled SMD = -0.04, 95%CI: -0.141 to 0.070, $I^2 = 74.72\%$) (data not shown). Results did not change when we explored separately the association between physical activity and the ratio AB42/AB40 (pooled SMD = -0.083, 95%CI: -0.216 to 0.049, $I^2 = 79.85\%$),

Physical activity and amyloid beta

Author, year - ES	n	Tissue	Design	Aβ isoform	Population					Weight %	6 Estimate [9	5%CI]
de Souto Barreto et al., 2015 - ES1 ²⁰	268	PET	Cross	SUVR	Mixed			÷		5.46%	0.09 [-0.03,	0.21]
de Souto Barreto et al., 2015 - S1 - ES1 ²⁰	65	PET	Cross	SUVR	Mixed		i		1	1.28%	0.04 [-0.21,	0.29]
de Souto Barreto et al., 2015 - S2 - ES1 ²⁰	169	PET	Cross	SUVR	Mixed		F			3.42%	0.09 [-0.06,	0.24]
Brown et al. 2013 - ES157	116	PET	Cross	SUVR	Congnitively normal		⊢ −	÷		5.72%	-0.16 [-0.35,	0.02]
Brown et al. 2017 - ES156	138	PET	Cross	SUVR	Cognitively impaired		⊢			4.26%	0.05 [-0.12,	0.21]
Brown et al. 2017 - ES3 ⁵⁶	139	PET	Cross	SUVR	Cognitively impaired			÷		4.29%	-0.14 [-0.31,	0.03]
Head et al. 2012 - ES1 ⁵⁵	163	PET	Cross	MCBP	Congnitively normal					6.86%	-0.19 [-0.34,	-0.03]
Kimura et al., 2020 ⁴⁶	118	PET	Cross	SUVR	Cognitively impaired		—	Ļ.		5.77%	-0.04 [-0.23,	0.14]
Liang et al., 2010 - ES1 ⁵³	54	PET	Cross	MCBP	Congnitively normal					3.38%	-0.47 [-0.74,	-0.19]
Mihaila et al., 2019 - ES1 ³⁷	41	PET	Cross	SUVR	Cognitively impaired		н	-	4	2.24%	-0.02 [-0.34,	0.30]
Mihaila et al., 2019 - ES2 ³⁷	41	PET	Long	SUVR	Cognitively impaired		H			2.24%	0.05 [-0.27,	0.37]
Müller et al., 2018 - ES1 ⁵⁴	224	PET	Cross	SUVR	Cognitively impaired		⊢	-		7.91%	-0.13 [-0.26,	0.00]
Okonkwo et al., 2014 ⁴⁹	186	PET	Cross	SUVR	Congnitively normal		F			7.30%	0.05 [-0.10,	0.19]
Pedrero-Chamizo et al., 2022 ⁵⁰	78 ^a	PET	Cross	SUVR	Congnitively normal		H			4.44%	0.05 [-0.18,	0.28]
Pedrini et al., 2021 - ES158	143	PET	Cross	SUVR	Congnitively normal		⊢	÷		6.42%	-0.07 [-0.23,	0.10]
Rabin et al., 2019 ⁴⁵	182	PET	Cross	DVR	Congnitively normal			÷ 1		7.23%	0.01 [-0.14,	0.16]
Sohn et al., 2022 ⁵⁰	260	PET	Cross	SUVR	Mixed		F	÷.		8.38%	0.06 [-0.06,	0.18]
Treyer et al., 2021 ⁵²	49	PET	Cross	SUVR	Congnitively normal	H	•	i.		3.13%	-0.32 [-0.61,	-0.03]
Vemuri et al., 2012 ⁴⁸	515	PET	Cross	SUVR	Mixed		⊢∎			10.25%	-0.07 [-0.16,	0.02]
RE Model: <i>p</i> < 0.001, <i>l</i> ² = 49.92 %							•			100%	-0.06 [-0.11,	0.00]
								<u> </u>				
					-0.8	-0.5	-0.2					
					-0.0	5.0	0.2	0.1	0.1			
					Negative assoc	ation	Positive as:	sociation				

Fig. 3. Forest plot of pooled effect size and confidence intervals of observational studies exploring the association between physical activity and brain A β . ^a Sample represents the number of participants in the extreme group. 95%CI=95% confidence interval; A β = amyloid beta; cross = cross-sectional studies; DVR = distribution volume ratio; ES = effect sizes; long = longitudinal cohort studies; MCBP = mean cortical blinding potentials; PET = positron emission tomography; RE = random effect; SUVR = standardized uptake value ratio.

AB42 (pooled SMD = -0.091, 95%CI: -0.190 to 0.009, $I^2 = 54.45\%$), and AB40 (pooled SMD = -0.046, 95%CI: -0.163 to 0.071, $I^2 = 66.57\%$). Only a single study reported the ratio AB40/AB42.⁵⁸ Therefore, these data were

excluded from the general pool, and we were not able to meta-analyze them separately.

Moderation analysis by population (cognitively normal vs. cognitively impaired) revealed no moderation effect in CSF

Author, year - ES	n	Tissue	e Design	Aβ isofor	m Population				Weight %	Estimate [95% CI]
Alwardat et al. 2019 ⁴¹	23*	CSF	Cross	Αβ42	Cognitively impaired				2.17%	0.76 [0.32, 1.20]
Baker et al. 2012 - S1 ⁵⁹	18	CSF	Cross	Αβ42	Congnitively normal ⊢				1.56%	-0.26 [-0.76, 0.25]
Baker et al. 2012 - S2 ⁵⁹	23	CSF	Cross	Αβ42	Cognitively impaired	·			2.07%	-0.01 [-0.45, 0.43]
Brown et al. 2017 - ES2 ⁵⁶	111	CSF	Cross	Αβ42	Cognitively impaired	H			7.08%	0.12 [-0.07, 0.30]
Brown et al. 2017 - ES4 ⁵⁶	120	CSF	Cross	Αβ42	Cognitively impaired	<u> </u>			7.67%	0.01 [-0.18, 0.19]
Head et al. 2012 - ES2 ⁵⁵	165	CSF	Cross	Αβ42	Congnitively normal		⊢ ∎−−1		12.10%	0.23 [0.08, 0.39]
Hou et al., 2021 ⁴²	1108	CSF	Cross	Αβ42	Congnitively normal		⊨∎⊣		26.79%	0.08 [0.02, 0.14]
Liang et al., 2010 - ES2 ⁵³	56	CSF	Cross	Αβ42	Congnitively normal				5.21%	0.27 [0.01, 0.54]
Müller et al., 2018 - ES2 ⁵⁴	224	CSF	Cross	Αβ42	Cognitively impaired		- i		14.60%	0.16 [0.03, 0.29]
Reijs et al., 2017 ⁴⁰	464	CSF	Cross	Αβ42	Cognitively impaired	F	-- -1		20.74%	0.05 [-0.04, 0.14]
RE Model: p < 0.001, l² = 3	8 %						•		100%	0.12 [0.05, 0.18]
						1		1	г	
					-0.8	-0.28	0.25	0.78	1.3	
						Negative association	Positive association	1		

Fig. 4. Forest plot of pooled effect size and confidence intervals of observational studies exploring the association between physical activity and CSF A β . *=Sample represents the number of participants in the extreme groups (low vs. high PA groups). 95%CI=95% confidence interval; A β =amyloid beta; CSF=Cerebrospinal fluid; cross=cross-sectional studies; ES=effect sizes; long=longitudinal cohort studies; RE=random effect.

M. Rodriguez-Ayllon et al.

Author, year - ES	n	Tissue	Design	Aβ isoform	Population	Wei	ght % Estimate [95% CI]
Brown et al. 2013 - ES2 ⁵⁷	540	Blood	Cross A	ιβ42/40 (INNO-BIA)	Congnitively normal		4.34% -0.15 [-0.24, -0.07]
Brown et al. 2013 - ES357	533	Blood	Cross	Aβ42/40 (ELISA)	Congnitively normal	⊢−−−− 4	4.29% -0.10 [-0.19, -0.02]
Stillman et al., 2017 - ES638	149	Blood	Long	Αβ42/40	Congnitively normal	⊢−−−− −	3.91% -0.21 [-0.37, -0.05]
Stillman et al., 2017 - ES338	149	Blood	Long	Αβ42/40	Congnitively normal	▶ <u> </u>	3.91% -0.15 [-0.31, 0.01]
Raffin et al., 202162	465	Blood	Cross	Αβ42/40	Congnitively normal	⊢- ∎1	20.98% 0.05 [-0.04, 0.14]
Subgroup effect on Aβ42/40 (Q =	= 13.68	8, <i>df</i> = 4	, p < .01;	$I^2 = 79.85\%, \tau^2 =$	0.00)	-	-0.083 [-0.216, 0.049]
Brown et al. 2013 - ES457	540	Blood	Cross	Aβ42 (INNO-BIA)	Congnitively normal	F	4.34% -0.04 [-0.12, 0.04]
Brown et al. 2013 - ES657	540	Blood	Cross	Aβ42 (ELISA)	Congnitively normal	⊢ →	4.34% -0.04 [-0.12, 0.04]
Stillman et al., 2017 - ES538	149	Blood	Long	Αβ42	Congnitively normal	⊢	3.91% -0.18 [-0.34, -0.02]
Stillman et al., 2017 - ES238	149	Blood	Long	Αβ42	Congnitively normal	F	3.91% -0.16 [-0.32, 0.00]
Pedrini et al., 2022 - ES2 ⁵⁸	143	Blood	Cross	Αβ42	Congnitively normal	, ∎ i	9.17% -0.20 [-0.37, -0.04]
Daniele et al., 2018 - ES2 ⁶¹	48	Blood	Cross	Αβ42	Congnitively normal	· · · · · · · · · · · · · · · · · · ·	5.32% 0.14 [-0.15, 0.43]
Daniele et al., 2018 - ES161	54	Blood	Cross	Αβ42	Congnitively normal	·	6.03% -0.00 [-0.28, 0.27]
Subgroup effect on Aβ42 (Q = 8.4	41, df	= 6, p =	0.21; / ²	$= 54.45\%, \tau^2 = 0.0$	0)	•	-0.091 [-0.190, 0.009]
Brown et al. 2013 - ES757	533	Blood	Cross	Aβ40 (ELISA)	Congnitively normal	r	4.29% -0.01 [-0.10, 0.08]
Brown et al. 2013 - ES5 ⁵⁷	533	Blood	Cross	Aβ40 (INNO-BIA)	Congnitively normal		4.29% 0.09 [0.01, 0.18]
Stillman et al., 2017 - ES438	149	Blood	Long	Αβ40	Congnitively normal	⊢	3.91% -0.07 [-0.23, 0.09]
Stillman et al., 2017 - ES1 ³⁸	149	Blood	Long	Αβ40	Congnitively normal	⊢	3.91% -0.06 [-0.22, 0.10]
Pedrini et al., 2022 - ES358	143	Blood	Cross	Αβ40	Congnitively normal	⊢	9.17% -0.17 [-0.34, -0.01]
Subgroup effect on Aβ40 (Q = 9.6	67, df	= 4, p =	0.05; / ²	$= 66.57\%, \tau^2 = 0.0$	0)	-	-0.046 [-0.163, 0.071]
Overall effect (Q = 38.87, df = 16, p <	.01; / ²	= 68.02%	$\tau^2 = 0.00$)		•	100% -0.06 [-0.15, 0.03]
						-0.4 -0.2 0 0.2 0.4 0.6	
						Negative association Positive association	

Fig. 5. Forest plot of pooled effect size and confidence intervals of observational studies exploring the association between physical activity and blood A β . 95%CI = 95% confidence interval; A β = amyloid beta; cross = cross-sectional studies; ES = effect sizes; ELISA = enzyme-linked immunoassay; long = longitudinal cohort studies; Q = the Q test is typically used to test the homogeneity of effect sizes as well as the impact of moderators; INNO-BIA = a commercial kit to assess A β (Innogenetics, Inc., Gent, Belgium).

analysis (Omnibus test of moderators = 8.44, p = 0.88) and brain (Omnibus test of moderators = 6.68, p = 0.2) analysis (see Fig. 6). We did not run moderation analyses by population in blood because all participants were cognitively normal. Lastly, we did not find evidence of publication bias based on visual observation of the funnel plots and Egger's tests (Supplementary Figs. 3–5).

4. Discussion

The main findings of this review suggest that exercise interventions of 12-52 weeks have a medium effect on blood A β levels in middle-aged and older adults. Notably, only a few studies were included in the meta-analysis, and the results

were not statistically significant. Therefore, caution is needed in interpreting these findings. In addition, there were not enough studies in the literature to meta-analyze the effects of physical activity on the brain and CSF A β . In observational studies, the association of physical activity with brain and blood A β was not significant, but higher levels of physical activity were positively associated with A β in the CSF.

4.1. Meta-analysis of intervention studies: The effects of physical activity on $A\beta$

Our intervention meta-analysis identified that physical activity moderately reduces the levels of blood $A\beta$ in middleaged and older individuals. However, the results were not



Fig. 6. Forest plot of moderation analysis of observational studies by population. All studies included in these analyses used the isoform A β 42 when they assessed A β in the CSF. 95%CI = 95% confidence interval; A β = amyloid beta; CSF = cerebrospinal fluid. Q = the Q test is typically used to test the homogeneity of effect sizes as well as the impact of moderators.

Physical activity and amyloid beta

statistically significant, and the number of studies assessing AB only in the blood in the final meta-analyses was limited. The published results regarding the correlation of blood AB with brain and CSF AB are conflicting, and its effect on other AD biomarkers is still unclear.⁸ Altogether these findings make it difficult to conclude whether physical activity could be a protective factor for AD through its effect on AB. We are not suggesting that physical activity does not positively affect cognitive health in older adults, just that there are other possible mechanisms, such as exercise-induced changes in the expression of neurotrophic factors and neurotransmitters, that might explain the protective role of physical activity in neurocognitive health during late adulthood.⁶³ Additionally, it is important to note that several questions remain unanswered at present. First, the effect of physical activity on AB might differ between cognitively normal and cognitively impaired people as well as in younger and older adults. In this regard, animal studies¹⁹ suggest that physical activity might only be effective in reducing AB accumulation within an early preclinical stage. Accordingly, individuals who are already experiencing deterioration in cognitive function may be too advanced in the disease course for physical activity to modify AB deposition. However, in our meta-analysis, we were surprised to observe higher effects in older people, which is out of line with this hypothesis. Altogether, due to the contradictory findings, the heterogeneity between studies, and the low number of studies included in our metaanalysis, more intervention studies are needed to develop a full picture of the role of age and cognitive health status in the effects of physical activity on AB in both middle-aged and older adults. Second, the measurements of AB were heterogeneous (only a single study used brain $A\beta$,¹⁴ one used CSF $A\beta$,¹⁵ and 6 used blood $A\beta^{17,31-35}$). Because of the heterogeneity between studies, only studies that assessed $A\beta$ in the blood were included in the meta-analysis. Thus, additional welldesigned RCTs with a standardized AB measurement protocol are needed to confirm or refute the effects of physical activity on brain, CSF, and blood AB levels in cognitively normal and cognitively impaired individuals. Third, the effects of physical activity on AB became significant and the total effect size increased when the study carried out by Kim et al.³³ (which assessed A β 30 min after the final session in the 16th week) was excluded from the meta-analysis. Consequently, future studies might explore the acute and chronic effects of physical activity on A β by standardizing the time interval between the final session of the physical activity intervention and the postintervention AB assessment. Lastly, our meta-analysis also suggested the type of intervention (i.e., aerobic vs. others) might affect AB differently. Therefore, further studies might explore whether the effect of physical activity on A β varies by type of intervention.

4.2. Meta-analyses of observational studies: The associations between physical activity and $A\beta$

Meta-analyses of observational studies in middle-aged and older individuals indicated that physical activity was significantly associated only with CSF A β . However, these results should be interpreted with caution because most studies included in the meta-analyses were of a cross-sectional design. Of the 4 longitudinal cohort studies included in this systematic review, 2 were performed in cognitively normal older adults.^{38,39} while the other 2 were carried out in individuals with mild cognitive impairment⁴⁰ or Down syndrome.³⁷ Notably, the 2 studies focused on individuals with cognitive impairments did not find any significant association.^{37,40} A possible explanation for this could be that physical activity is less influential in individuals whose accumulation of AB in the brain reaches a certain threshold. Of note, longitudinal PET studies in humans have demonstrated that AB accumulates slowly and plateaus at the onset of clinical symptoms.^{64–66} The plateau of $A\beta$ may indicate that amyloid pathology reaches dynamic equilibrium or inactivity at the clinical stage of dementia. Although we observed a tendency in favor of this hypothesis, population characteristics of included studies (cognitively normal vs. cognitively impaired) did not moderate the relationship between physical activity and AB in our metaanalysis. Overall, further prospective population-based cohort studies are needed to provide greater insight on the longitudinal association between physical activity and $A\beta$ by comparing (a) preclinical and clinical stages of AD, and (b) individuals of different ages and cognitive characteristics.

In addition to the participants' characteristics, other differences (e.g., the instrument used to assess AB measurements in the brain, CSF, or blood) might be considered. For instance, gold-standard measurements, such as PET, offer the most accurate way of evaluating the relationship between physical activity and brain AB levels antemortem. However, despite its advantages, PET scanning is not able to quantify small changes in brain AB, especially over short periods, which could partially explain the null associations.⁶⁷ In contrast, other AB biofluid markers in the CSF seem to be more sensitive and dynamic indicators of the relationship between physical activity and A β in human populations,⁶⁸ which could partially explain our findings. In addition to CSF and brain AB, there has been a growing interest in developing new techniques to measure blood $A\beta$ due to its being a less expensive and invasive approach. However, until recently, most studies exploring the association between physical activity and blood Aβ have used ELISA kits, which showed high variability.¹⁹ This issue might be attenuated by using high-performance blood-based AB assays, such as mass spectrometry.⁴ Remarkably, differences were also found in the direction of the associations between physical activity and the various measurements of A β . Specifically, the relationship between physical activity and CSF A β was positive, which is contrary to what was expected in the brain. Although more accurate assays are needed to understand whether physical activity differentially modulates AB levels in the brain, CSF, or blood, previous studies showed that $A\beta$ levels increase in AD when it is assessed in the brain with PET⁶⁹ and decrease when measured in the CSF.⁷⁰ One possible explanation for this is that aggregation of A β into plaques and greater retention of the peptide in the brain results in reduced diffusion of A β into the CSF. Lastly, although most studies suggest higher levels of brain

and blood A β are predictive of AD, there are still some inconsistencies between studies.⁸ Therefore, more replication within cohorts and more standardization with respect to analytical procedures focusing on A β are necessary to understand the relationship between physical activity and blood A β .

4.3. Literature gaps and future research

- There is a need to determine whether the effect of physical activity on $A\beta$ varies by type, duration, intensity, or frequency of physical activity.
- Intervention studies might assess Aβ in the blood, the brain, and the CSF to explore whether the effect of exercise on Aβ might vary by type of tissue.
- Future intervention studies might compare the exercise group with a standardized non-active control group (e.g., participants who continued their usual routines) to avoid any effect-size bias.
- More large-scale multicenter intervention studies are needed to test the effectiveness of physical activity for modulating $A\beta$ levels.
- Long-term physical activity interventions are needed to more definitively test the effect of physical activity on PET-quantified brain Aβ. For CSF and blood Aβ, the use of high-performance blood-based Aβ assays is needed to reduce the variability in previous studies.
- Future interventions should standardize the time interval between the final session of the intervention and the brain, blood, and CSF A β post-intervention assessment since results may differ (e.g., positive or negative direction) when assessing A β in acute *vs*. chronic conditions.
- Longitudinal population-based studies are needed to explore the long-term associations between physical activity and $A\beta$, and to compare the general population with preclinical and clinical stages of AD.
- Due to the possibility of bi-directionality, longitudinal cohort studies with physical activity and $A\beta$ data at 2 time points are needed to determine the possibility of reverse causality.
- More studies are needed to disambiguate populations most affected by physical activity as well as set the key stages for appreciating Aβ changes (e.g., cognitively normal *vs.* cognitively impaired).
- In addition to the Aβ path, more research is needed to unravel the potential mechanisms linking physical activity with cognition in the elderly.

4.4. Limitations and strengths

Our review has some limitations. First, there were not sufficient studies in each population (i.e., cognitively normal and cognitively impaired) to identify individuals most affected by physical activity. Second, we could not explore the moderating roles of several variables that might have influenced the meta-analytic results (e.g., Apolipoprotein E (APOE) genotype). Third, our search was limited to middle-aged and older adults. Since amyloid deposition can occur in an earlier stage of life,⁷¹ future studies can include younger populations to explore whether physical activity might affect A β differently in earlier stages of life. Lastly, given the scarcity of studies in the meta-analysis, future RCTs on this topic are needed.

This systematic review also has some strengths. First, it follows the PRISMA guidelines for systematic review methodology. Second, we registered the study in PROS-PERO databases before starting the specific search. Third, we organized a list of excluded articles and the reasons for exclusion. Finally, we included different databases and all types of study designs.

5. Conclusion

Research in the field of cognitive aging has attempted to understand the reasons for individual variability in cognitive decline. This body of work is highly convinced that physical activity affects cognitive and brain health outcomes.⁷² However, more research is needed to understand how physical activity shapes the aging brain.⁷² In this context, the present systematic review suggests physical activity might moderately reduce blood AB, which is one possible mechanism for delivering the benefits of physical activity, in older people. However, since the results neared but did not reach statistical significance, they should be interpreted with caution, especially given the methodological limitations observed in some of the included studies. Moreover, increased physical activity was associated with higher levels of $A\beta$ only when it was assessed in the CSF. Overall, due to the small number of intervention studies included in the meta-analysis, and to the equivocal findings provided by the observational studies, more studies are needed to understand the role of physical activity in modulating brain, CSF, and blood AB levels, as well as the implications for cognitive health. Additionally, future studies should continue exploring the potential mechanisms responsible for the positive effects of physical activity on cognition to spur the development of more effective interventions and stimulate the identification of cost-efficient alternative therapies for preventing and treating AD. Finally, although our systematic review and meta-analysis cannot provide direct clinical practice changes, we identified gaps in the literature as well as future perspectives that might guide new research directions in the cognitive aging field.

Acknowledgments

MRA was funded by the Ramón Areces Foundation. IEC is supported by the Spanish Ministry of Science and Innovation (RYC2019-027287-I) and the Spanish Ministry of Economy and Competitiveness (RT I^2 018-095284-J-100). PSU is supported by a grant from ANID/BECAS Chile (Grant No. 72180543) and through a Margarita Salas grant from the Spanish Ministry Universities.

Physical activity and amyloid beta

Authors' contributions

MRA participated in the design/conception, data analysis, interpretation, manuscript preparation, and revision; PSU participated in the design, data analysis, interpretation, and manuscript revision; CAÁ participated in the design, data analysis, and manuscript preparation; PMG participated in the data analysis, interpretation, and manuscript preparation and revision; MÁO participated in the data analysis; CMH participated in the data analysis; manuscript preparation, and revision; MGR, BB, and KIE participated in the interpretation and manuscript revision; IEC participated in the design/conception, data analysis, interpretation, manuscript preparation, and revision. All authors agreed to be accountable for all aspects of the work, contributed to the manuscript writing. All authors have read and approved the final version of the manuscript, and agree with the order of presentation of the authors.

Competing interests

The authors declare that they have no competing interests.

Supplementary materials

Supplementary materials associated with this article can be found in the online version at doi:10.1016/j.jshs.2023.08.001.

References

- Deture MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. *Mol Neurodegener* 2019;14:1–18.
- Reitz C, Mayeux R. Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers. *Biochem Pharmacol* 2014;88:640–51.
- Keuss SE, Coath W, Nicholas JM, et al. Associations of β-amyloid and vascular burden with rates of neurodegeneration in cognitively normal members of the 1946 British Birth Cohort. *Neurology* 2022;99:e129–41.
- Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers for Alzheimer's disease. *Nature* 2018;554:249–54.
- Fagan AM, Mintun MA, Mach RH, et al. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans. *Ann Neurol* 2006;59:512–9.
- Landau SM, Lu M, Joshi AD, et al. Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β-amyloid. *Ann Neurol* 2013;74:826–36.
- Palmqvist S, Zetterberg H, Blennow K, et al. Accuracy of brain amyloid detection in clinical practice using cerebrospinal fluid β-amyloid 42: A cross-validation study against amyloid positron emission tomography. *JAMA Neurol* 2014;71:1282–9.
- Wang X, Sun Y, Li T, Cai Y, Han Y. Amyloid-β as a blood biomarker for Alzheimer's disease: A review of recent literature. J Alzheimers Dis 2020;73:819–32.
- Kivipelto M, Mangialasche F, Ngandu T. Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease. *Nat Rev Neurol* 2018;14:653–66.
- Moore KM, Girens RE, Larson SK, et al. A spectrum of exercise training reduces soluble Aβ in a dose-dependent manner in a mouse model of Alzheimer's disease. *Neurobiol Dis* 2016;85:218–24.
- Adlard PA, Perreau VM, Pop V, Cotman CW. Voluntary exercise decreases amyloid load in a transgenic model of Alzheimer's disease. J Neurosci 2005;25:4217–21.
- 12. Vasconcelos-Filho FSL, da Rocha Oliveira LC, de Freitas TBC, et al. Effect of involuntary chronic physical exercise on beta-amyloid protein in experimental models of Alzheimer's disease: Systematic review and

meta-analysis. *Exp Gerontol* 2021;**153**: 111502. doi:10.1016/j. exger.2021.111502.

- Tarumi T, Rossetti H, Thomas BP, et al. Exercise training in amnestic mild cognitive impairment: A one-year randomized controlled trial. J Alzheimers Dis 2019;71:421–33.
- Vidoni ED, Morris JK, Watts A, et al. Effect of aerobic exercise on amyloid accumulation in preclinical Alzheimer's: A 1-year randomized controlled trial. *PLoS One* 2021;16: e0244893. doi:10.1371/journal. pone.0244893.
- 15. Jensen CS, Portelius E, Siersma V, et al. Cerebrospinal fluid amyloid beta and tau concentrations are not modulated by 16 weeks of moderate- to high-intensity physical exercise in patients with Alzheimer disease. *Dement Geriatr Cogn Disord* 2016;42:146–58.
- Yokoyama H, Okazaki K, Imai D, et al. The effect of cognitive-motor dual-task training on cognitive function and plasma amyloid β peptide 42/ 40 ratio in healthy elderly persons: A randomized controlled trial. *BMC Geriatr* 2015;15:60. doi:10.1186/s12877-015-0058-4.
- Kwon Y, Park S, Kim E, Park H. Effects of combined exercise on β-amyloid and DHEAs in elderly women. *Jpn J Phys Fitness Sports Med* 2007;56:149–56.
- Ebrahimi K, Majdi A, Baghaiee B, Hosseini SH, Sadigh-Eteghad S. Physical activity and beta-amyloid pathology in Alzheimer's disease: A sound mind in a sound body. *EXCLI J* 2017;16:959–72.
- Brown BM, Peiffer J, Rainey-Smith SR. Exploring the relationship between physical activity, beta-amyloid and tau: A narrative review. *Ageing Res Rev* 2019;50:9–18.
- **20.** de Souto Barreto P, Andrieu S, Rolland Y. Physical activity and β-amyloid brain levels in humans: A systematic review. *J Prev Alzheimers Dis* 2015;**2**:56–63.
- Frederiksen KS, Gjerum L, Waldemar G, Hasselbalch SG. Physical activity as a moderator of Alzheimer pathology: A systematic review of observational studies. *Curr Alzheimer Res* 2019;16:362–78.
- Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* 2009;**339**:b2535. doi:10.1016/j.jcms.2010.11.001.
- Moola S, Munn Z, Tufanaru C, et al. *Chapter 7: Systematic reviews of etiology and risk. JBI Manual for Evidence Synthesis. JBI.* 2020. doi:10.46658/JBIMES-20-08. Available at: https://synthesismanual.jbi.global. [accessed 10.09.2022].
- 24. Molina-Garcia P, Migueles JH, Cadenas-Sanchez C, et al. A systematic review on biomechanical characteristics of walking in children and adolescents with overweight/obesity: Possible implications for the development of musculoskeletal disorders. *Obes Rev* 2019;**20**:1033–44.
- Haynes A, Kersbergen I, Sutin A, Daly M, Robinson E. A systematic review of the relationship between weight status perceptions and weight loss attempts, strategies, behaviours and outcomes. *Obes Rev* 2018;19:347–63.
- 26. van Ekris E, Altenburg TM, Singh AS, Proper KI, Heymans MW, Chinapaw MJM. An evidence-update on the prospective relationship between childhood sedentary behaviour and biomedical health indicators: A systematic review and meta-analysis. *Obes Rev* 2016;17:833–49.
- Sterne JA, Egger M, Smith GD. Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. BMJ 2001;323:101–5.
- Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
- Habeck CW, Schultz AK. Community-level impacts of white-tailed deer on understorey plants in North American forests: A meta-analysis. *AoB Plants* 2015;7:plv119. doi:10.1093/aobpla/plv119.
- Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343:d4002. doi:10.1136/bmj.d4002.
- Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise on mild cognitive impairment: A controlled trial. *Arch Neurol* 2010;67:71–9.
- 32. Hyang-Beum L, Tae-Sang K. Effects of a band training intervention on dementia factors of Alzheimer's disease, cognitive functions, and functional physical fitness among elderly women with suspected mild dementia. *Korea Soc Wellness* 2021;16:357–63. [in Korean].

- 33. Kim JH, Jung YS, Kim JW, Ha MS, Ha SM, Kim DY. Effects of aquatic and land-based exercises on amyloid beta, heat shock protein 27, and pulse wave velocity in elderly women. *Exp Gerontol* 2018;108:62–8.
- 34. Zhang S-A. Effects of walking and band exercising on cognitive function, dementia-related factor and senior fitness of the elderly women with mild cognitive impairment. *Korea Soc Wellness* 2021;16:291–8. [in Korean].
- 35. Baek SH, Hong GR, Min DK, Kim EH, Park SK. Effects of functional fitness enhancement through taekwondo training on physical characteristics and risk factors of dementia in elderly women with depression. *Int J Environ Res Public Health* 2021;18:7961. doi:10.3390/ijerph18157961.
- 36. Poinsatte K, Smith EE, Torres VO, et al. T and B cell subsets differentially correlate with amyloid deposition and neurocognitive function in patients with amnestic mild cognitive impairment after one year of physical activity. *Exerc Immunol Rev* 2019;25:34–49.
- Mihaila I, Handen BL, Christian BT, et al. Leisure activity, brain β-amyloid, and episodic memory in adults with Down syndrome. *Dev Neurobiol* 2019;**79**:738–49.
- Stillman CM, Lopez OL, Becker JT, et al. Physical activity predicts reduced plasma β amyloid in the Cardiovascular Health Study. Ann Clin Transl Neurol 2017;4:284–91.
- **39.** Stojanovic M, Jin Y, Fagan AM, et al. Physical exercise and longitudinal trajectories in Alzheimer disease biomarkers and cognitive functioning. *Alzheimer Dis Assoc Disord* 2020;**34**:212–9.
- Reijs BLR, Vos SJB, Soininen H, et al. Association between later life lifestyle factors and Alzheimer's disease biomarkers in non-demented individuals: A longitudinal descriptive cohort study. J Alzheimers Dis 2017;60:1387–95.
- Alwardat M, Schirinzi T, di Lazzaro G, et al. Association between physical activity and dementia's risk factors in patients with Parkinson's disease. *J Neural Transm (Vienna)* 2019;126:319–25.
- Hou XH, Xu W, Bi YL, et al. Associations of healthy lifestyles with cerebrospinal fluid biomarkers of Alzheimer's disease pathology in cognitively intact older adults: The CABLE study. *Alzheimers Res Ther* 2021;13:81. doi:10.1186/s13195-021-00822-7.
- Buchman AS, Dawe RJ, Yu L, et al. Brain pathology is related to total daily physical activity in older adults. *Neurology* 2018;90:e1911–9.
- 44. Landau SM, Marks SM, Mormino EC, et al. Association of lifetime cognitive engagement and low β-amyloid deposition. Arch Neurol 2012;69:623–9.
- 45. Rabin JS, Klein H, Kirn DR, et al. Associations of physical activity and β-amyloid with longitudinal cognition and neurodegeneration in clinically normal older adults. *JAMA Neurol* 2019;**76**:1203–10.
- 46. Kimura N, Aso Y, Yabuuchi K, et al. Association of modifiable lifestyle factors with cortical amyloid burden and cerebral glucose metabolism in older adults with mild cognitive impairment. *JAMA Netw Open* 2020;3: e205719. doi:10.1001/jamanetworkopen.2020.5719.
- 47. de Souto Barreto P, Andrieu S, Payoux P, et al. Physical activity and amyloid-β brain levels in elderly adults with intact cognition and mild cognitive impairment. *J Am Geriatr Soc* 2015;63:1634–9.
- Vemuri P, Lesnick TG, Przybelski SA, et al. Effect of lifestyle activities on Alzheimer disease biomarkers and cognition. *Ann Neurol* 2012;72:730–8.
- Okonkwo OC, Schultz SA, Oh JM, et al. Physical activity attenuates agerelated biomarker alterations in preclinical AD. *Neurology* 2014;83:1753–60.
- 50. Sohn BK, Byun MS, Yi D, et al. Late-life physical activities moderate the relationship of amyloid-β pathology with neurodegeneration in individuals without dementia. *J Alzheimers Dis* 2022;86:441–50.
- Pedrero-Chamizo R, Szoeke C, Dennerstein L, Campbell S. Influence of physical activity levels and functional capacity on brain β-amyloid deposition in older women. *Front Aging Neurosci* 2021;13: 697528. doi:10.3389/fnagi.2021.697528.
- Treyer V, Meyer RS, Buchmann A. Physical activity is associated with lower cerebral beta-amyloid and cognitive function benefits from lifetime experience—A study in exceptional aging. *PLoS One* 2021;16: e0247225. doi:10.1371/journal.pone.0247225.

- Liang KY, Mintun MA, Fagan AM, et al. Exercise and Alzheimer's disease biomarkers in cognitively normal older adults. *Ann Neurol* 2010;68:311–8.
- 54. Müller S, Preische O, Sohrabi HR, et al. Relationship between physical activity, cognition, and Alzheimer pathology in autosomal dominant Alzheimer's disease. *Alzheimers Dement* 2018;14:1427–37.
- Head D, Bugg JM, Goate AM, et al. Exercise engagement as a moderator of the effects of APOE genotype on amyloid deposition. *Arch Neurol* 2012;69:636–43.
- 56. Brown BM, Sohrabi HR, Taddei K, et al. Habitual exercise levels are associated with cerebral amyloid load in presymptomatic autosomal dominant Alzheimer's disease. *Alzheimers Dement* 2017;13:1197–206.
- 57. Brown BM, Peiffer JJ, Taddei K, et al. Physical activity and amyloid-β plasma and brain levels: Results from the Australian Imaging, Biomarkers and Lifestyle Study of Ageing. *Mol Psychiatry* 2013;18:875–81.
- Pedrini S, Chatterjee P, Nakamura A, et al. The association between Alzheimer's disease-related markers and physical activity in cognitively normal older adults. *Front Aging Neurosci* 2022;14: 771214. doi:10.3389/ fnagi.2022.771214.
- 59. Baker LD, Bayer-Carter JL, Skinner J, et al. High-intensity physical activity modulates diet effects on cerebrospinal amyloid-β levels in normal aging and mild cognitive impairment. *J Alzheimers Dis* 2012;28:137–46.
- 60. Daniele S, Pietrobono D, Fusi J, et al. α-Synuclein aggregates with β-amyloid or Tau in human red blood cells: Correlation with antioxidant capability and physical exercise in human healthy subjects. *Mol Neurobiol* 2018;55:2653–75.
- Daniele S, Pietrobono D, Fusi J, et al. α-Synuclein aggregated with tau and β-amyloid in human platelets from healthy subjects: Correlation with physical exercise. *Front Aging Neurosci* 2018;10:17. doi:10.3389/ fnagi.2018.00017.
- 62. Raffin J, Rolland Y, Aggarwal G, et al. Associations between physical activity, blood-based biomarkers of neurodegeneration, and cognition in healthy older adults: The MAPT study. J Gerontol A Biol Sci Med Sci 2021;76:1382–90.
- Umegaki H, Sakurai T, Arai H. Active life for brain health: A narrative review of the mechanism underlying the protective effects of physical activity on the brain. *Front Aging Neurosci* 2021;13: 761674. doi:10.3389/fnagi.2021.761674.
- **64.** Kadir A, Almkvist O, Forsberg A, et al. Dynamic changes in PET amyloid and FDG imaging at different stages of Alzheimer's disease. *Neurobiol Aging* 2012;**33**:198. e1–14.
- 65. Villemagne VL, Pike KE, Chételat G, et al. Longitudinal assessment of Aβ and cognition in aging and Alzheimer's disease. *Ann Neurol* 2011;69:181–92.
- 66. Bateman RJ, Xiong C, Benzinger TLS, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 2012;367:795–804.
- 67. Villemagne VL, Burnham S, Bourgeat P, et al. Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: A prospective cohort study. *Lancet Neurol* 2013;**12**:357–67.
- Jack Jr CR, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: An updated hypothetical model of dynamic biomarkers. *Lancet Neurol* 2013;12:207–16.
- Palmqvist S, Insel PS, Stomrud E, et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer's disease. *EMBO Mol Med* 2019;11:e11170. doi:10.15252/emmm.201911170.
- Blennow K. Cerebrospinal fluid protein biomarkers for Alzheimer's disease. *NeuroRx* 2004;1:213–25.
- Bischof GN, Rodrigue KM, Kennedy KM, Devous MD, Park DC. Amyloid deposition in younger adults is linked to episodic memory performance. *Neurology* 2016;87:2562–6.
- Erickson KI, Donofry SD, Sewell KR, Brown BM, Stillman CM. Cognitive aging and the promise of physical activity. *Annu Rev Clin Psychol* 2022;18:417–42.